New Breast Implant Recall in the EU Prompts Need for VeriTeQ’s Device Traceability Technology

VeriTeQ’s Q Inside Safety Technology is Currently Being Used in the EU and UK with its Partner’s Motiva Implant Matrix® Breast Implants

VeriTeQ Corporation (“VeriTeQ” or “Company”) (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, today commented on the latest breast implant recall in the European Union. Breast implants manufactured by French company Cereplas are being recalled by The National Security Agency of Medicines and Health Products (“ANSM”) due to concerns regarding sterilization and equipment used in production of the implants.

The ANSM in the EU has suspended the marketing, distribution and use of breast implants and sizers from Cereplas until the company achieves compliance with regulations, which include control of the process of sterilization and qualification of equipment used in production. Cereplas’ CE marking Certificates for its breast implants have also been suspended.

“This new recall of breast implants is the latest example of regulators pushing for higher standards for medical devices following the PIP scare in the EU,” said Scott R. Silverman, Chairman and CEO of VeriTeQ. “Furthermore, it serves as another reminder for manufacturers, physicians and patients of the need for advanced device traceability technologies like VeriTeQ’s Q Inside Safety Technology, that can externally retrieve the device information without the stress and risk of a re-operation.”

VeriTeQ’s Q Inside Safety Technology acts as an electronic serial number in breast implants and other implantable and reusable medical devices to identify them during a recall or adverse event to help ensure patient safety.

VeriTeQ is currently working with breast implant manufacturer Establishment Labs, S.A. (“EL”), which markets its Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology in the EU. EL’s CE cleared Motiva Implant Matrix® product line with VeriTeQ’s Q Inside Safety Technology offers the world’s first externally identifiable breast implant.

By including VeriTeQ’s FDA cleared Q Inside Safety Technology in breast implants and other medical devices, manufacturers, physicians and patients will have access to a secure online database to retrieve device-specific data such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology also provides an extra level of protection to the patient in the event of a recall or other safety event as it provides accurate and immediate confirmation of the origin of a patient’s medical device.

About EL

Establishment Labs is a privately held, global breast, body and facial aesthetic company with offices in Florida, Costa Rica and Belgium, that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All its products are produced in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC. For more information on EL, please visit www.establishmentlabs.com.

About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

Statements in this press release about our future expectations, including, without limitation, the likelihood that by including VeriTeQ’s FDA cleared Q Inside Safety Technology in breast implants and other medical devices, manufacturers, physicians and patients will have access to a secure online database to retrieve device-specific data such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to commercially launch its Q Inside Safety Technology in the EU and UK in 2014; VeriTeQ’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ’s Forms 10-Q, filed on August 9, 2013 and November 14, 2013, and future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

VeriTeQ CorporationAllison Tomek, 561-846-7003atomek@veriteqcorp.comorRedChip CompaniesBrendan Hopkins, 1-800-RED-CHIP (733-2447), ext. 134Bhopkins@redchip.com

VeriTeQ (CE) (USOTC:VTEQ)
Historical Stock Chart
From Mar 2024 to Apr 2024